PCN248 ESTIMATING THE UNBIASED OS-BENEFIT FOR APALUTAMIDE (APA) VERSUS ANDROGEN DEPRIVATION THERAPY (ADT) IN PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) FROM SPARTAN, ADJUSTING FOR SUBSEQUENT THERAPY USING RAN ...
May 1, 2019, 00:00
10.1016/j.jval.2019.04.369
https://www.valueinhealthjournal.com/article/S1098-3015(19)30561-3/fulltext
Title :
PCN248 ESTIMATING THE UNBIASED OS-BENEFIT FOR APALUTAMIDE (APA) VERSUS ANDROGEN DEPRIVATION THERAPY (ADT) IN PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) FROM SPARTAN, ADJUSTING FOR SUBSEQUENT THERAPY USING RAN ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)30561-3&doi=10.1016/j.jval.2019.04.369
First page :
Section Title :
Open access? :
No
Section Order :
10019